RedHill Biopharma (RDHL) Corporate presentation summary

Corporate highlights and financials

• Focuses on U.S. commercialization and development of drugs for GI, infectious diseases, and oncology, with a strong commercial footprint and late-stage pipeline.

• FY 2025 net revenues were $7.8M, with a cash balance of $4.1M and gross margin of 74.6%.

• Equity financing capacity stands at $31.7M as of May 2026.

• Strategic partnership with Cumberland Pharmaceuticals for Talicia, including a $4M investment and 30% stake in the global Talicia business.

Key commercial product: Talicia

• Talicia (omeprazole magnesium, amoxicillin, rifabutin) is FDA-approved for H. pylori infection in adults and launched in the U.S. and UAE.

• Listed as a first-line option in the 2024 ACG guideline and covered by major U.S. formularies, reaching over 200 million American lives.

• Demonstrates >90% eradication rates in adherent populations and negligible resistance to component antibiotics.

• U.S. patent protection until 2042 and QIDP designation grants market exclusivity through 2027.

Clinical and scientific validation

• Two positive Phase 3 studies for Talicia showed high efficacy and safety, with no serious adverse events.

• Peer-reviewed literature and guidelines support Talicia as a preferred first-line therapy, especially as it avoids clarithromycin resistance.

• Broad managed care coverage includes Aetna, OptumRx, Express Scripts, Medi-Cal, Humana Medicare Part D, VA, and TennCare.